Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Erythropoietin Payments To Major Dialysis Facilities Cut In House Medicare/Child Health Package

This article was originally published in The Pink Sheet Daily

Executive Summary

"Large" dialysis centers providing erythropoietin-stimulating agents could see Medicare payments reduced to average sales price plus 2 percent, under a Medicare/child health bill scheduled for markup by two House committees July 26. Medicare Part B currently reimburses ESAs at ASP + 6 percent

You may also be interested in...



Part D Formulary Changes Would Permit Enrollees To Switch Medicare Plans Mid-Year, Under House Child Health Bill

Medicare provisions in bill slated for July 26 markup include making six “protected” formulary classes permanent and requiring that dual eligibles be assigned to plans covering the most common brand and generic products.

Part D Formulary Changes Would Permit Enrollees To Switch Medicare Plans Mid-Year, Under House Child Health Bill

Medicare provisions in bill slated for July 26 markup include making six “protected” formulary classes permanent and requiring that dual eligibles be assigned to plans covering the most common brand and generic products.

Report On Bundling ESA/Dialysis Payments For Medicare Expected In July

CMS’ Norwalk previews report at House Ways and Means hearing

Topics

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel